Compile Data Set for Download or QSAR
maximum 50k data
Found 786 with Last Name = 'johns' and Initial = 'ba'
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50170870(CHEMBL3805182)
Affinity DataIC50:  0.600nMAssay Description:Inhibition of pseudotype HIV1 integrase strand transfer activity assessed as reduction in viral replication in HIV1 infected human CIP4 cells after 2...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50170867(CHEMBL3806067)
Affinity DataIC50:  0.700nMAssay Description:Inhibition of pseudotype HIV1 integrase strand transfer activity assessed as reduction in viral replication in HIV1 infected human CIP4 cells after 2...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50170867(CHEMBL3806067)
Affinity DataIC50:  1nMAssay Description:Inhibition of pseudotype HIV1 integrase strand transfer activity assessed as reduction in viral replication in in HIV1 infected human CIP4 cells afte...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50484379(CHEMBL1917873)
Affinity DataIC50:  1nMAssay Description:Inhibition of HIV1 integrase strand transfer by biochemical assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50489299(CHEMBL2316125)
Affinity DataIC50:  2nMAssay Description:Inhibition of HIV1 integrase strand transfer activityMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294719(US10112899, Example 196)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGag-Pol polyprotein [1148-1435](Human immunodeficiency virus type 1)
Gsk

LigandPNGBDBM28274(1,3,4-oxadiazole substituted naphthyridine, 42 | 4...)
Affinity DataIC50:  2nMAssay Description:Purified recombinant integrase was first combined in a complex with biotinylated donor DNA- streptavidin-coated SPA beads. The complex was preincubat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetGag-Pol polyprotein [1148-1435](Human immunodeficiency virus type 1)
Gsk

LigandPNGBDBM28269(1,3,4-oxadiazole substituted naphthyridine, 37 | 3...)
Affinity DataIC50:  2nMAssay Description:Purified recombinant integrase was first combined in a complex with biotinylated donor DNA- streptavidin-coated SPA beads. The complex was preincubat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294814(US10112899, Example 285)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294834(US10112899, Example 305)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294851(US10112899, Example 321)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294679(US10112899, Example 158)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294680(US10112899, Example 159)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294683(US10112899, Example 162)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294691(US10112899, Example 169)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294692(US10112899, Example 170)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294693(US10112899, Example 171)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294657((S)-2-(tert-butoxy)-2-((R)-2-(5-fluoro-2-methylben...)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294700(US10112899, Example 178)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294706(US10112899, Example 184)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294708(US10112899, Example 186)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294714(US10112899, Example 191)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGag-Pol polyprotein [1148-1435](Human immunodeficiency virus type 1)
Gsk

LigandPNGBDBM28239(2-(7-{5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2...)
Affinity DataIC50:  2nMAssay Description:Purified recombinant integrase was first combined in a complex with biotinylated donor DNA- streptavidin-coated SPA beads. The complex was preincubat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294738((S)-2-(tert-butoxy)-2-((M)-6-(8-fluoro-5-methylchr...)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50170591(CHEMBL2403116)
Affinity DataIC50:  2nMAssay Description:Inhibition of pseudotype HIV1 integrase strand transfer activity assessed as reduction in viral replication in HIV1 infected human CIP4 cells after 2...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50170870(CHEMBL3805182)
Affinity DataIC50:  2nMAssay Description:Inhibition of pseudotype HIV1 integrase strand transfer activity assessed as reduction in viral replication in in HIV1 infected human CIP4 cells afte...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294622((S)-2-(tert-butoxy)-2-((R)-2-(3,3-difluoropiperidi...)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294623(US10112899, Example 103)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294624((S)-2-(tert-butoxy)-2-((M)-2-(3,3-dimethylbutanoyl...)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294657((S)-2-(tert-butoxy)-2-((R)-2-(5-fluoro-2-methylben...)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294658(US10112899, Example 137)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294659(US10112899, Example 138)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294661(US10112899, Example 140)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294666(US10112899, Example 145)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294670(US10112899, Example 149)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294673(US10112899, Example 152)
Affinity DataIC50:  2nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGag-Pol polyprotein [1148-1435](Human immunodeficiency virus type 1)
Gsk

LigandPNGBDBM28239(2-(7-{5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2...)
Affinity DataIC50:  2nMpH: 7.2 T: 2°CAssay Description:Purified recombinant integrase was first combined in a complex with biotinylated donor DNA- streptavidin-coated SPA beads. The complex was preincubat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50170604(CHEMBL3805585)
Affinity DataIC50:  2.20nMAssay Description:Inhibition of pseudotype HIV1 integrase strand transfer activity assessed as reduction in viral replication in HIV1 infected human CIP4 cells after 2...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50062551(CHEBI:76010 | Dolutegravir | GSK1349572 | S-349572)
Affinity DataIC50:  2.70nMAssay Description:Inhibition of HIV-1 integrase strand transfer activity using [3H]-DNA as substrate preincubated for 60 mins prior to substrate addition measured afte...More data for this Ligand-Target Pair
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50483553(CHEBI:76007 | Dolutegravir Sodium | GSK1349572 | G...)
Affinity DataIC50:  2.70nMAssay Description:Inhibition of strand transfer activity of Human immunodeficiency virus 1 Integrase using [3H]labeled target DNA as substrate after 45 mins by scintil...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294709(US10112899, Example 187)
Affinity DataIC50:  3nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGag-Pol polyprotein [1148-1435](Human immunodeficiency virus type 1)
Gsk

LigandPNGBDBM28285(1,3,4-oxadiazole substituted naphthyridine, 53 | N...)
Affinity DataIC50:  3nMAssay Description:Purified recombinant integrase was first combined in a complex with biotinylated donor DNA- streptavidin-coated SPA beads. The complex was preincubat...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50492496(Cabotegravir | GSK-1265744A | GSK1265744 | GSK1265...)
Affinity DataIC50:  3nMAssay Description:Inhibition of HIV-1 integrase strand transfer activity using [3H]-DNA as substrate preincubated for 60 mins prior to substrate addition measured afte...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50489263(CHEMBL2316126)
Affinity DataIC50:  3nMAssay Description:Inhibition of HIV1 integrase strand transfer activityMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50489280(CHEMBL2311585)
Affinity DataIC50:  3nMAssay Description:Inhibition of HIV1 integrase strand transfer activityMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Glaxosmithkline

Curated by ChEMBL
LigandPNGBDBM50489287(CHEMBL2316116)
Affinity DataIC50:  3nMAssay Description:Inhibition of HIV1 integrase strand transfer activityMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294779(US10112899, Example 251)
Affinity DataIC50:  3nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294847(US10112899, Example 317)
Affinity DataIC50:  3nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294850(US10112899, Example 320)
Affinity DataIC50:  3nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetIntegrase(Human immunodeficiency virus 1)
Viiv Healthcare

US Patent
LigandPNGBDBM294678(US10112899, Example 157)
Affinity DataIC50:  3nMAssay Description:Antiviral HIV activity and cytotoxicity values for compounds of the invention from Table 1 were measured in parallel in the HTLV-1 transformed cell l...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 786 total ) | Next | Last >>
Jump to: